148608-53-1

Basic information

• Product Name: 5-formylcytidine
• Synonyms: 5-formylcytidine
• CAS NO: 148608-53-1
• Molecular Formula: C10H13 N3 O6
• Molecular Weight: 271.23
• Mol File: 148608-53-1.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 594.9°Cat760mmHg
• Flash Point: 313.6°C
• Appearance: /
• Density: 1.91g/cm³
• Vapor Pressure: 1.24E-16mmHg at 25°C
• Refractive Index: 1.755
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Sonicated), Methanol (Slightly, Heated), Water (Slightly, Heated
• PKA: 13.48±0.70(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 5-formylcytidine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-formylcytidine(148608-53-1)
• EPA Substance Registry System: 5-formylcytidine(148608-53-1)

Safety Data

• Hazardous Substances Data: 148608-53-1(Hazardous Substances Data)

Usage

Uses

5-Formylcytidine is a modefied nucleoside found at the first position of the anticodon of bovine mitochondrial tRNAMet.

InChI:InChI=1/C10H13N3O6/c11-8-4(2-14)1-13(10(18)12-8)9-7(17)6(16)5(3-15)19-9/h1-2,5-7,9,15-17H,3H2,(H2,11,12,18)/t5-,6-,7-,9-/m1/s1

Upstream product

• 19235-17-7 5-hydroxymethyl-1-(β-D-ribofuranosyl)cytosine 
• 329897-80-5 Acetic acid 1-((3aR,4R,6R,6aR)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-2-oxo-4-[1,2,4]triazol-1-yl-1,2-dihydro-pyrimidin-5-ylmethyl ester 
• 163496-05-7 C₃₃H₂₇N₅O₈ 
• 329897-79-2 Acetic acid 1-((3aR,4R,6R,6aR)-2,2-dimethyl-6-trityloxymethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl)-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-ylmethyl ester 
• 329897-76-9 4-amino-1-[5-(tert-butyl-diphenyl-silanyloxymethyl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-5-hydroxymethyl-1H-pyrimidin-2-one 
• 329897-78-1 2',3'-O-isopropylidene-5'-O-trityl-5-(hydroxymethyl)uridine 
• 329897-81-6 5-hydroxymethyl-2',3'-O-isopropylidene-5'-O-tritylcytidine 
• 329897-75-8 4-amino-1-[5-(tert-butyl-diphenyl-silanyloxymethyl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidin-2-one 
• 59237-68-2 2',3',5'-tri-O-benzoyl-5-methylcytidine 
• 10526-27-9 2',3'-O-(isopropylidene)-5'-O-(triphenylmethyl)uridine 
• 3180-76-5 2',3',5'-tri-O-benzoyluridine 
• 6974-32-9 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose 
• 329897-77-0 4-Amino-1-[(2R,3R,4S,5R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-3,4-dihydroxy-tetrahydro-furan-2-yl]-2-oxo-1,2-dihydro-pyrimidine-5-carbaldehyde 
• 2140-61-6 5-methylcytidine 

Relevant articles and documents

The existence of 5-hydroxymethylcytosine and 5-formylcytosine in both DNA and RNA in mammals

We developed a novel strategy by oxidation-derivatization combined mass spectrometry analysis for the determination of 5-hydroxymethylcytosine and 5-formylcytosine in both DNA and RNA. We reported the presence of 5-formylcytosine in RNA of mammals and found that ascorbic acid and hydroquinone can increase the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine in DNA and RNA.

SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS

This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.